FFA
CTXR icon

Farther Finance Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Farther Finance Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-343
Closed -$425 – 5485
2025
Q3 		$425 Buy
+343
New +$478 ﹤0.01% 4579
2024
Q3 		– Sell
-3
Closed -$43 – 4025
2024
Q2 		$43 Hold
3
– – ﹤0.01% 3707
2024
Q1 		$82 Buy
+3
New +$55 ﹤0.01% 3409

Other funds holding CTXR

HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Farther Finance Advisors's CTXR Position: Q4 2025 in Review

Farther Finance Advisors sold out of Citius Pharmaceuticals (CTXR) in Q4 2025, closing a stake of 343 shares — an estimated $425 sold.

Farther Finance Advisors first reported a position in CTXR in Q1 2024 and held it in 3 quarters. The position peaked at $425 in Q3 2025. 39 funds tracked by Wall St. Rank hold CTXR as of Q4 2025.

  • Farther Finance Advisors reported no remaining Citius Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 343 Citius Pharmaceuticals shares in Q4 2025, an estimated $425.
  • Farther Finance Advisors first reported a position in Citius Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Farther Finance Advisors's Citius Pharmaceuticals position peaked at $425 in Q3 2025.
  • 39 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2025.

Based on Farther Finance Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.